530 results on '"McArthur, H."'
Search Results
2. P125 Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study
3. Changing patterns of shifting cultivation in Timor-Leste.
4. Abstract ES10-2: Immune therapy in the (neo) adjuvant setting
5. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
6. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
7. VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC
8. 1611P Health-related quality of life, vaccine uptake and immune response among cancer patients undergoing treatment during the COVID-19 pandemic
9. Effects of a green tea extract, Polyphenon E, on systemic biomarkers of growth factor signalling in women with hormone receptor-negative breast cancer
10. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer
11. Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials
12. Engineering of complex polyketide biosynthesis — insights from sequencing of the monensin biosynthetic gene cluster
13. 134TiP A phase III trial of nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2− primary breast cancer: CheckMate 7FL
14. KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer
15. Studies on the Penicillin - Sensitive D, D-Carboxypeptidase of Bacillus Coagulans
16. Thawing, refreezing and frozen storage effects on muscle functionality and sensory attributes of frozen cod (Gadus morhua)
17. 1LBA LBA Oral - Adjuvant chemotherapy with or without atezolizumab for stage II and III triple-negative breast cancer: final analysis of the ALEXANDRA/ IMpassion030 phase 3 trial.
18. Abstract OT3-04-03: KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab versus placebo in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk early-stage ER+/HER2– breast cancer
19. Abstract OT3-05-02: ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early triple negative breast cancer
20. Abstract OT3-04-02: The DORA trial: A non-comparator randomised phase II multi-center maintenance study of olaparib alone or olaparib in combination with durvalumab in platinum treated advanced triple negative breast cancer (TNBC)
21. Characterisation and evaluation of fischer-tropsch catalysts prepared hydrothermally
22. 24TiP - KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer
23. Percutaneous cryoablation in 4T1 murine breast cancer model
24. Phase Ib/II open-label study of Ad-RTS-hIL-12 + veledimex gene therapy in chemotherapy-responsive locally advanced or metastatic breast cancer patients
25. A network approach to developing immuno-oncology combinations in Canada.
26. Defects in Airey Houses
27. Durability of cementatious products and concrete
28. Value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer
29. FEATURED ABSTRACT, Tumor and systemic immune responses to pre-operative cryoablation plus immune therapy with ipilimumab in early stage breast cancer
30. Abstract No. 237 - Percutaneous cryoablation in 4T1 murine breast cancer model
31. The Organization and Support of Scientific Research and Development in Mainland China. Yuan-li Wu Robert B. Sheeks
32. Effects of a green tea extract, Polyphenon E, on systemic biomarkers of growth factor signalling in women with hormone receptor-negative breast cancer
33. A practical field extraction method for non-invasive monitoring of hormone activity in the black rhinoceros
34. 280P - Phase Ib/II open-label study of Ad-RTS-hIL-12 + veledimex gene therapy in chemotherapy-responsive locally advanced or metastatic breast cancer patients
35. Abstract P4-13-01: A pilot study of pre-operative (Pre-op), single-dose ipilimumab (Ipi) and/or cryoablation (Cryo) in women (pts) with early stage/resectable breast cancer (ESBC)
36. Abstract P5-02-01: Regulated intratumoral expression of IL-12 in combination with cytotoxic agents as a strategy for the treatment of metastatic breast cancer
37. Standardized uptake value (SUV) by positron emission tomography/computed tomography (PET/CT) as a prognostic variable in metastatic breast cancer (MBC).
38. Standardized uptake value (SUV) by positron emission tomography/computed tomography (PET/CT) as a prognostic variable in metastatic breast cancer (MBC).
39. 3:30 PM, Abstract No. 286 - FEATURED ABSTRACT, Tumor and systemic immune responses to pre-operative cryoablation plus immune therapy with ipilimumab in early stage breast cancer
40. ChemInform Abstract: Biosynthesis of the Shikimate-Derived Starter Unit of the Immunosuppressant Ascomycin: Stereochemistry of the 1,4-Conjugate Elimination.
41. Use of adjuvant trastuzumab with chemotherapy in women with small, node-negative, HER2-positive breast cancers.
42. High Resolution Comparative Genomic Hybridization (CGH) Indicates That Genomic Profiles Are Very Heterogeneous for HER2 and TOP2A in FISH-Amplified Human Breast Cancer Specimens.
43. Troponins Do Not Predict Cardiotoxicity in a Pilot Study of Adjuvant Bevacizumab (B) Plus Dose-Dense Doxorubicin/Cyclophosphamide (AC) Followed by Nanoparticle Albumin-Bound Paclitaxel (nab-P).
44. Evaluation of the correlation of baseline blood pressure (BP) and plasma renin activity (PRA) with bevacizumab (B)-mediated hypertension in patients with early-stage breast cancer
45. Adjuvant dose-dense doxorubicin-cyclophosphamide x 4 with or without bevacizumab is safe: no evidence of short-term changes in left ventricular ejection fraction.
46. Incidence and severity of sensory neuropathy (SN) with bevacizumab (B) added to dose-dense (dd) doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound (nab) paclitaxel (P) in patients (pts) with early stage breast cancer (BC)
47. Dose-dense (dd) doxorubicin-cyclophosphamide (AC) X 4 and short-term changes in left ventricular ejection fraction (LVEF) alone or with bevacizumab (B) in patients (pts) with early stage breast cancer (BC)
48. Osteonecrosis of the jaw (ONJ) among intravenous (IV) bisphosphonate- and/or bevacizumab-treated patients (pts) at Memorial Sloan-Kettering Cancer Center (MSKCC)
49. Impact of risk-reducing oophorectomy on quality of life in women at risk for ovarian cancer
50. Standards and future strategies in adjuvant chemotherapy treatments
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.